Rodman & Renshaw Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Rani Therapeutics Holdings (NASDAQ:RANI) with a Buy rating and a price target of $10.
June 13, 2024 | 5:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Rani Therapeutics Holdings with a Buy rating and a price target of $10.
The initiation of coverage with a Buy rating and a price target of $10 by Rodman & Renshaw is likely to positively impact Rani Therapeutics Holdings' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100